Vaginal Estrogen as First-Line Therapy for Recurrent Urinary Tract Infections in Postmenopausal Women and Risk...

Area of Science:

• Urology
• Gynecology
• Geriatrics

Background:

• Recurrent urinary tract infections (rUTIs) significantly impact postmenopausal women's quality of life.
• Vaginal estrogen therapy is a common treatment for urogenital atrophy, which can contribute to rUTIs.

Purpose of the Study:

• To determine the effectiveness of vaginal estrogen cream alone for treating rUTIs in postmenopausal women.
• To identify risk factors associated with treatment failure, necessitating additional therapies.

Main Methods:

• Retrospective cohort study of postmenopausal women with rUTIs over 29 months.
• Inclusion criteria: new-onset rUTIs treated with vaginal estrogen cream as first-line therapy.
• Log-binomial regression analyzed associations between treatment failure and patient characteristics.

Main Results:

• 67.7% of patients experienced symptom improvement or resolution with vaginal estrogen cream alone.
• Women with concomitant urinary incontinence were 2.3 times more likely to require additional therapy.
• No significant differences in demographic or clinical characteristics were noted between therapy groups.

Conclusions:

• Vaginal estrogen cream alone is effective in managing rUTIs for a majority of postmenopausal women.
• Urinary incontinence is a significant risk factor for treatment failure in this population.
• Further research may explore combined therapies for women with concurrent urinary incontinence.